The people driving clearnote health

Supported By World Leading Expertise

ClearNote Health's advisors and board of directors include world leading scientists and industry veterans with decades of demonstrated success.

Meet Our Leadership Team

ClearNote Health has built a world-class multi-disciplinary team focused on applying our unique epigenomic platform to make long-term cancer survival a reality for more people.

Dave Mullarkey
Dave Mullarkey

Chief Executive Officer

Samuel Levy, PhD

Chief Scientific Officer

Wayne Volkmuth, PhD

Senior Vice President, Informatics & Data Discovery

Jeffrey M. Venstrom, MD

Chief Medical Officer

Anna Bergamaschi, PhD

Vice President, Product Development

Eric Nilson

Vice President, Enterprise IS&T

Shimul Chowdhury, PhD, FACMG

Vice President, Laboratory Operations

Gulfem Guler, PhD

Vice President, Translational Research, Head of Biopharma Development

Jeremiah R. (Jeremy) Bennett

Head of Marketing

Irene Hsieh

Vice President of Regulatory Affairs

Dr. Daniel Black, MBA

General Manager of International Markets

Alan Ashworth PhD, FRS

  • Cancer biomarkers and therapeutics, DNA repair/synthetic lethality
  • President, Helen Diller Comprehensive Cancer Center
  • SVP for Cancer Services, UCSF Health
  • Professor, Hematology Oncology, UCSF

David A. Diamond, MD, FACRO

  • Clinical advisor to ClearNote since inception
  • More than 20 years of clinical oncology experience
  • Former Chair of the Florida Board of Medicine
  • Former Chancellor of the American College of Radiation Oncology
  • Princeton University A.B. & University of Florida M.D.
  • Post-graduate training at Yale and Washington University St. Louis

Stephen Quake, D. Phil

  • Pioneer in liquid biopsy, single cell genomics, microfluidics
  • Head of Science, Chan Zuckerberg Initiative (CZI)
  • Professor, Bioengineering and applied physics Stanford University
  • Member of all three National Academies – Science, Engineering, and Medicine
  • Past Investigator, Howard Hughes Medical Institute

J. Craig Venter, PhD

  • Pioneer in sequencing Human Genome at Celera Genomics
  • Pioneer in genomic medicine, founder of Human Longevity Inc.
  • Founder of J. Craig Venter Institute (JCVI)

Mattias Westman

  • International finance and investments
  • Founding Partner, Prosperity Capital Management
  • Active global cross-border investor
  • Stockholm School of Economics

Stephen Quake, D. Phil

  • Pioneer in liquid biopsy, single cell genomics, microfluidics
  • Head of Science, Chan Zuckerberg Initiative (CZI)
  • Professor, Bioengineering and applied physics Stanford University
  • Member of all three National Academies – Science, Engineering, and Medicine
  • Past Investigator, Howard Hughes Medical Institute

Tina S. Nova, PhD

  • Pioneer in molecular-based diagnostics in oncology
  • President and CEO, Decipher Biosciences (acquired Veracyte)
  • Former President and CEO, Genoptix (acquired Novartis)
  • Prior executive leadership positions, Molecular Stethoscope, Illumina and Nanogen
  • Biotechnology leadership Ligand Pharmaceuticals, Hybritech

Dave Mullarkey

  • Life Sciences industry leader with an extensive track record of success in the cell free DNA diagnostics space, DNA sequencing instrument development, and operating in CLIA and IVD environment
  • Proven executive track record of C-level leadership scaling life sciences companies globally to successful exits across pharmaceuticals, diagnostics and life science tools
  • Most recent roles included President and CEO at Omniome, President and COO at Ariosa Diagnostics and Lifecycle Leader and Site Head at Roche
  • Decades of growth-oriented executive experience across different sizes and stages of companies both private and public (Omniome, Roche, Ariosa Diagnostics, Valeant Pharmaceuticals, Johnson & Johnson, Eli Lilly and Company, Dow Pharmaceuticals).